Key Points

  • Zoom is expected to report second-quarter revenue of $1.27 billion, up from $1.22 billion a year earlier, as the company seeks to extend its 15-quarter streak of revenue beats.
  • Analysts forecast earnings of $1.48 per share, slightly below the $1.53 reported in the comparable quarter last year.
  • Enterprise growth, the impact of the Common Room acquisition and the potential value of Zoom's private stake in Anthropic could shape investor sentiment beyond the headline earnings figures.
hero

Zoom Communications heads into its second-quarter earnings report with an unusually strong record against Wall Street expectations. The company has exceeded analyst revenue estimates for 15 consecutive quarters, setting a high bar for another quarterly report.

Analysts expect revenue to reach $1.27 billion, compared with $1.22 billion in the same period last year. The increase represents continued top-line expansion, although the pace remains relatively moderate compared with the rapid growth Zoom experienced earlier in its corporate history.

The ability to extend its revenue-beat streak could therefore matter as much as the absolute growth rate. Investors increasingly judge mature software businesses on their capacity to sustain predictable expansion while adapting their products to changing technology trends, particularly as artificial intelligence reshapes enterprise software.

Enterprise Business and AI Become Key Variables

BTIG analyst Allan Verkhovski maintained a Buy rating and a $125 price target ahead of the results, pointing to strong fundamentals and potential acceleration in Zoom’s Enterprise segment. The analyst argues that the stock’s 29% gain so far this year has been supported by improving top-line momentum and comparatively low exposure to AI-related disruption.

That distinction is important for Zoom. Rather than competing directly with many AI-native software businesses, the company is attempting to incorporate AI capabilities into its broader communications platform while continuing to deepen its enterprise relationships. Growth in the Enterprise segment could therefore provide a more durable source of expansion than relying on consumer or smaller-business demand alone.

Investors may also look for details regarding Zoom’s acquisition of Common Room, an AI intelligence platform. Any evidence that the acquisition is contributing strategically or financially could strengthen the narrative that Zoom is using AI as a growth opportunity rather than simply defending its existing business.

Anthropic Stake Adds a Different Dimension

One of the more unusual factors surrounding the earnings report is Zoom’s private investment in Anthropic. Verkhovski highlighted the growing value of that stake as one factor supporting the stock’s performance and believes it could remain relevant through a potential Anthropic initial public offering.

The stake introduces an additional layer to Zoom’s investment story because its potential value is not directly tied to quarterly operating revenue. If Anthropic’s valuation rises, investors could increasingly view Zoom as holding a strategic financial asset alongside its core communications business.

However, the potential value of a private-company investment should not overshadow operating fundamentals. Zoom still needs to demonstrate sustainable enterprise growth, effective AI integration and disciplined execution to justify a stronger long-term valuation.

What Investors Will Watch Next

Zoom’s second-quarter results will ultimately test whether its recent operating momentum can continue. A revenue beat would extend an already exceptional streak, while stronger Enterprise performance could provide evidence that the company’s growth is becoming more resilient.

At the same time, investors will watch whether earnings of $1.48 per share can outperform expectations despite the forecast decline from last year’s $1.53. Commentary surrounding Common Room, AI strategy and the Anthropic investment could prove equally important as the market assesses Zoom’s growth opportunities beyond traditional video communications.


Comparison, examination, and analysis between investment houses

Leave your details, and an expert from our team will get back to you as soon as possible

    * This article, in whole or in part, does not contain any promise of investment returns, nor does it constitute professional advice to make investments in any particular field.

    To read more about the full disclaimer, click here
    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?
    • omer bar
    • •
    • 8 Min Read
    • •
    • ago 14 hours

    SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast? SKN | Could Delta’s Higher Fares Offset Rising Fuel Costs as the Airline Cuts Its 2026 Profit Forecast?

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    • ago 14 hours
    • •
    • 8 Min Read

    Delta Air Lines has lowered its 2026 profit expectations as soaring jet fuel costs weigh on earnings, highlighting the challenge

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?
    • Ronny Mor
    • •
    • 6 Min Read
    • •
    • ago 2 days

    SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom? SKN | Could Samsung’s Record Profit Signal Another Major Phase of the AI Chip Boom?

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    • ago 2 days
    • •
    • 6 Min Read

    Samsung Electronics is projecting its strongest quarterly profitability on record, underscoring the extraordinary impact that the artificial intelligence boom is

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?
    • Ronny Mor
    • •
    • 7 Min Read
    • •
    • ago 4 days

    SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments? SKN | Could Summit’s Ivonescimab Help AstraZeneca Build the Next Generation of Cancer Treatments?

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    • ago 4 days
    • •
    • 7 Min Read

    Summit Deal Puts Ivonescimab at the Center of AstraZeneca’s Strategy AstraZeneca is positioning its investment in Summit Therapeutics around the

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?
    • Lior mor
    • •
    • 8 Min Read
    • •
    • ago 4 days

    SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business? SKN | Could Boeing’s New Fighter Jet Wins Mark a Turning Point for Its Defense Business?

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing

    • ago 4 days
    • •
    • 8 Min Read

    Boeing Expands Its Position in Next-Generation Fighters Boeing has strengthened its position in the U.S. military aircraft market after securing